Illinois General Assembly - Bill Status for SB3024
Illinois General Assembly

Previous General Assemblies

 Bill Status of SB3024  102nd General Assembly


Short Description:  CONTR SUB-PMP-CONFIDENTIALITY

Senate Sponsors
Sen. Melinda Bush

House Sponsors
(Rep. Kathleen Willis - Joyce Mason - Deb Conroy, Nicholas K. Smith, La Shawn K. Ford, Edgar Gonzalez, Jr., Kelly M. Cassidy, Michael J. Zalewski and Camille Y. Lilly)

Last Action
DateChamber Action
  5/6/2022SenatePublic Act . . . . . . . . . 102-0751

Statutes Amended In Order of Appearance
720 ILCS 570/318


Synopsis As Introduced
Amends the Illinois Controlled Substances Act. Provides that in accordance with an agreement entered into with the Department of Human Services, an authorized employee of a county or municipal health department or the Department of Public Health shall have access to data from the prescription inquiry system for any of the following purposes: (1) developing education programs or public health interventions relating to specific prescribing practices, controlled substances and the prevention of fraud and abuse; or (2) conducting analyses and publish reports on prescribing trends in their respective jurisdictions. Provides that analyses and reports must not include information that identifies, by name, license, or address, any practitioner, dispenser, ultimate user, or other person administering a controlled substance. Provides that any county or municipal health department accessing data from the system shall implement appropriate technical and physical safeguards to ensure the privacy and security of data obtained from the system.

Senate Floor Amendment No. 1
Replaces everything after the enacting clause. Amends the Illinois Controlled Substances Act. Provides that, in accordance with a confidentiality agreement entered into with the Department of Human Services, a medical director, or a public health administrator and their delegated analysts, of a county or municipal health department or the Department of Public Health shall have access to data from the prescription monitoring system for any of the following purposes: (1) developing education programs or public health interventions relating to prescribing trends and controlled substance use; or (2) conducting analyses and publish reports on prescribing trends in their respective jurisdictions. Provides that, at a minimum, the confidentiality agreement entered into with the Department shall: (i) prohibit analysis and reports produced under subparagraph (2) from including information that identifies, by name, license, or address, any practitioner, dispenser, ultimate user, or other person administering a controlled substance; and (ii) specify the appropriate technical and physical safeguards that the county or municipal health department must implement to ensure the privacy and security of data obtained from the system. Provides that the data from the system shall not be admissible as evidence, nor discoverable in any action of any kind in any court or before any tribunal, board, agency, or person. Provides that the disclosure of any such information or data, whether proper or improper, shall not waive or have any effect upon its confidentiality, non-discoverability, or non-admissibility. Provides that, notwithstanding any other provision of the Act, neither the Prescription Monitoring Program nor any other person shall disclose any information in violation of the restrictions and requirements implemented under Public Act 102-527 concerning opioid treatment programs licensed or certified by the Department of Human Services' Division of Substance Use Prevention and Recovery that are authorized by the federal Drug Enforcement Administration to prescribe Schedule II, III, IV, or V controlled substances for the treatment of opioid use disorders.

Actions 
DateChamber Action
  1/5/2022SenateFiled with Secretary by Sen. Melinda Bush
  1/5/2022SenateFirst Reading
  1/5/2022SenateReferred to Assignments
  1/11/2022SenateAssigned to Health
  1/18/2022SenatePostponed - Health
  2/7/2022SenateDo Pass Health; 012-000-000
  2/7/2022SenatePlaced on Calendar Order of 2nd Reading February 8, 2022
  2/15/2022SenateSenate Floor Amendment No. 1 Filed with Secretary by Sen. Melinda Bush
  2/15/2022SenateSenate Floor Amendment No. 1 Referred to Assignments
  2/22/2022SenateSenate Floor Amendment No. 1 Assignments Refers to Health
  2/22/2022SenateSenate Floor Amendment No. 1 Recommend Do Adopt Health; 013-000-000
  2/23/2022SenateSecond Reading
  2/23/2022SenateSenate Floor Amendment No. 1 Adopted; Bush
  2/23/2022SenatePlaced on Calendar Order of 3rd Reading February 24, 2022
  2/25/2022SenateThird Reading - Passed; 049-000-000
  2/25/2022HouseArrived in House
  2/25/2022HouseChief House Sponsor Rep. Kathleen Willis
  2/25/2022HouseFirst Reading
  2/25/2022HouseReferred to Rules Committee
  3/7/2022HouseAssigned to Prescription Drug Affordability & Accessibility Committee
  3/14/2022HouseAdded Alternate Co-Sponsor Rep. Nicholas K. Smith
  3/15/2022HouseAdded Alternate Chief Co-Sponsor Rep. Joyce Mason
  3/16/2022HouseDo Pass / Short Debate Prescription Drug Affordability & Accessibility Committee; 016-004-000
  3/17/2022HousePlaced on Calendar 2nd Reading - Short Debate
  3/22/2022HouseSecond Reading - Short Debate
  3/22/2022HousePlaced on Calendar Order of 3rd Reading - Short Debate
  3/23/2022HouseAdded Alternate Co-Sponsor Rep. La Shawn K. Ford
  3/23/2022HouseAdded Alternate Co-Sponsor Rep. Edgar Gonzalez, Jr.
  3/24/2022HouseAdded Alternate Co-Sponsor Rep. Kelly M. Cassidy
  3/25/2022HouseAdded Alternate Chief Co-Sponsor Rep. Deb Conroy
  3/29/2022HouseThird Reading - Short Debate - Passed 090-020-000
  3/29/2022SenatePassed Both Houses
  3/29/2022HouseAdded Alternate Co-Sponsor Rep. Michael J. Zalewski
  3/29/2022HouseAdded Alternate Co-Sponsor Rep. Camille Y. Lilly
  4/27/2022SenateSent to the Governor
  5/6/2022SenateGovernor Approved
  5/6/2022SenateEffective Date January 1, 2023
  5/6/2022SenatePublic Act . . . . . . . . . 102-0751

Back To Top